{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T13:11:50Z","timestamp":1777554710545,"version":"3.51.4"},"reference-count":41,"publisher":"SAGE Publications","issue":"6S","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatitis"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1097\/der.0000000000000843","type":"journal-article","created":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T06:49:17Z","timestamp":1644994157000},"page":"S73-S82","source":"Crossref","is-referenced-by-count":6,"title":["Incidence of Bacterial and Nonbacterial Conjunctivitis in Patients With Atopic Dermatitis Treated With Dupilumab: A US Multidatabase Cohort Study"],"prefix":"10.1177","volume":"33","author":[{"given":"Maria C.","family":"Schneeweiss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Wyss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristyn","family":"Chin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan I.","family":"Silverberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arash","family":"Mostaghimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Schneeweiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,3,15]]},"reference":[{"issue":"2","key":"bib1-20221118","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"bib2-20221118","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jaad.2016.04.054","article-title":"Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): a phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD)","volume":"75","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"10013","key":"bib3-20221118","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","article-title":"Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial","volume":"387","year":"2016","journal-title":"Lancet"},{"issue":"24","key":"bib4-20221118","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","year":"2016","journal-title":"N Engl J Med"},{"issue":"10086","key":"bib5-20221118","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"bib6-20221118","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/all.14080","article-title":"Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: first clinical and biomarker results from the BioDay registry","volume":"75","year":"2020","journal-title":"Allergy"},{"issue":"10","key":"bib7-20221118","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1001\/jamadermatol.2018.2690","article-title":"Risk factors for dupilumab-associated conjunctivitis in patients with atopic dermatitis","volume":"154","year":"2018","journal-title":"JAMA Dermatol"},{"key":"bib8-20221118","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1097\/ICO.0000000000002262","article-title":"Dupilumab-associated conjunctivitis in patients with atopic dermatitis","volume":"39","year":"2020","journal-title":"Cornea"},{"issue":"3","key":"bib9-20221118","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40123-019-0191-9","article-title":"Ocular surface diseases induced by dupilumab in severe atopic dermatitis","volume":"8","year":"2019","journal-title":"Ophthalmol Therapy"},{"issue":"2","key":"bib10-20221118","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jaad.2020.09.084","article-title":"Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: a propensity score-matched cohort study","volume":"84","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"bib11-20221118","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jdin.2021.03.009","article-title":"Encounters and medication use for ocular surface disorders among patients treated with dupilumab: a cohort study","volume":"4","year":"2021","journal-title":"JAAD Int"},{"issue":"4","key":"bib12-20221118","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jclinepi.2004.10.012","article-title":"A review of uses of health care utilization databases for epidemiologic research on therapeutics","volume":"58","year":"2005","journal-title":"J Clin Epidemiol"},{"key":"bib13-20221118","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jclinepi.2016.04.014","article-title":"Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses","volume":"79","year":"2016","journal-title":"J Clin Epidemiol"},{"issue":"8","key":"bib14-20221118","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/pds.1926","article-title":"A basic study design for expedited safety signal evaluation based on electronic healthcare data","volume":"19","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"bib15-20221118","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/jdv.14888","article-title":"Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II","volume":"32","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"bib16-20221118","first-page":"327","article-title":"Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents","volume":"71","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"bib17-20221118","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/pds.3334","article-title":"The incident user design in comparative effectiveness research","volume":"22","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"bib18-20221118","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1471-2415-11-14","article-title":"Incidence of new coding for dry eye and ocular infection in open-angle glaucoma and ocular hypertension patients treated with prostaglandin analogs: retrospective analysis of three medical\/pharmacy claims databases","volume":"11","year":"2011","journal-title":"BMC Ophthalmol"},{"issue":"9","key":"bib19-20221118","doi-asserted-by":"crossref","first-page":"778","DOI":"10.18553\/jmcp.2007.13.9.778","article-title":"Economic burden of atopic manifestations in patients with atopic dermatitis\u2014analysis of administrative claims","volume":"13","year":"2007","journal-title":"J Manag Care Pharma"},{"key":"bib20-20221118","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2415-9-13","article-title":"Estimate of the direct and indirect annual cost of bacterial conjunctivitis in the United States","volume":"9","year":"2009","journal-title":"BMC Ophthalmol"},{"issue":"6","key":"bib21-20221118","doi-asserted-by":"crossref","first-page":"e015795","DOI":"10.1136\/bmjopen-2016-015795","article-title":"Risk of allergic conjunctivitis in patients with type 1 diabetes mellitus: a population-based retrospective cohort study","volume":"7","year":"2017","journal-title":"BMJ Open"},{"issue":"12","key":"bib22-20221118","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1093\/aje\/kwj149","article-title":"Variable selection for propensity score models","volume":"163","year":"2006","journal-title":"Am J Epidemiol"},{"key":"bib23-20221118","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","year":"1983","journal-title":"Biometrika"},{"issue":"suppl 2","key":"bib24-20221118","first-page":"69","article-title":"One-to-many propensity score matching in cohort studies","volume":"21","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"bib25-20221118","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1002\/sim.6058","article-title":"Metrics for covariate balance in cohort studies of causal effects","volume":"33","year":"2014","journal-title":"Stat Med"},{"issue":"25","key":"bib26-20221118","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","year":"2009","journal-title":"Stat Med"},{"issue":"11","key":"bib27-20221118","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1001\/jama.1988.03720110047033","article-title":"Meta-analysis. A quantitative approach to research integration","volume":"259","year":"1988","journal-title":"JAMA"},{"issue":"7126","key":"bib28-20221118","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1136\/bmj.316.7126.221","article-title":"Meta-analysis. Unresolved issues and future developments","volume":"316","year":"1998","journal-title":"BMJ"},{"issue":"3","key":"bib29-20221118","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/cpt.329","article-title":"Transparency and reproducibility of observational cohort studies using large healthcare databases","volume":"99","year":"2016","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"bib30-20221118","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.2337\/dc19-0069","article-title":"Using real-world data to predict findings of an ongoing phase IV cardiovascular outcome trial: cardiovascular safety of linagliptin versus glimepiride","volume":"42","year":"2019","journal-title":"Diabetes Care"},{"key":"bib31-20221118","first-page":"1002","article-title":"Emulating randomized clinical trials with nonrandomized real-world evidence studies: first results from the RCT DUPLICATE Initiative","volume":"143","year":"2010","journal-title":"Circulation"},{"issue":"23","key":"bib33-20221118","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","article-title":"Real-world evidence\u2014what is it and what can it tell us?","volume":"375","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"bib34-20221118","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjd.17869","article-title":"Conjunctivitis in dupilumab clinical trials","volume":"181","year":"2019","journal-title":"Br J Dermatol"},{"issue":"11","key":"bib35-20221118","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/j.ophtha.2013.03.044","article-title":"Topical cyclosporine in the treatment of allergic conjunctivitis: a meta-analysis","volume":"120","year":"2013","journal-title":"Ophthalmology"},{"key":"bib36-20221118","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.3389\/fimmu.2020.01907","article-title":"Research progress in atopic march","volume":"11","year":"2020","journal-title":"Front Immunol"},{"issue":"7","key":"bib37-20221118","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/jdv.15608","article-title":"Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy\u2014International Eczema Council survey and opinion","volume":"33","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"bib38-20221118","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s40268-019-00288-x","article-title":"A clinician's guide to the recognition and management of dupilumab-associated conjunctivitis","volume":"19","year":"2019","journal-title":"Drugs R D"},{"issue":"10","key":"bib39-20221118","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1002\/sim.2053","article-title":"The use of the propensity score for estimating treatment effects: administrative versus clinical data","volume":"24","year":"2005","journal-title":"Stat Med"},{"issue":"2","key":"bib40-20221118","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/pst.433","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies","volume":"10","year":"2011","journal-title":"Pharm Stat"},{"issue":"12","key":"bib41-20221118","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/ncprheum0652","article-title":"Primer: administrative health databases in observational studies of drug effects\u2014advantages and disadvantages","volume":"3","year":"2007","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"10 Supl 2","key":"bib42-20221118","first-page":"S131","article-title":"Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results","volume":"45","year":"2007","journal-title":"Med Care"}],"container-title":["Dermatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DER.0000000000000843","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:06:32Z","timestamp":1777399592000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1097\/DER.0000000000000843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,15]]},"references-count":41,"journal-issue":{"issue":"6S","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/der.0000000000000843","relation":{},"ISSN":["2162-5220","1710-3568"],"issn-type":[{"value":"2162-5220","type":"electronic"},{"value":"1710-3568","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3,15]]}}}